Table 2.
Comparison of butyrate effectiveness as an add-on therapy in achieving remission in different subgroups.
| Number of Patients | Study Group 72 |
Group A 29 |
Group B 43 |
p | |
|---|---|---|---|---|---|
| Mild disease (≤10 points) | All | 42 | 18 | 24 | - |
| Rem. | 25 (59.5%) | 9 (50%) | 16 (66.7%) | 0.276 | |
| Moderate/severe disease (>10 points) |
All | 30 | 11 | 19 | - |
| Rem. | 24 (80%) | 9 (81.8%) | 15 (78.9%) | 0.85 | |
| Excluding patients on steroids | All | 64 | 26 | 38 | - |
| Rem. | 31 48.4%) | 15 (57.7%) | 24 (63.2%) | 0.38 | |
| Excluding patients on antibiotics | All | 54 | 21 | 33 | - |
| Rem. | 40 (70.1%) | 14 (66.7%) | 26 (78.8%) | 0.322 | |
| Excluding patients on steroids, antibiotics and anti-TNF | All | 42 | 15 | 27 | - |
| Rem. | 29 (69.0%) | 9 (60.0%) | 20 (74.1%) | 0.344 | |
| Patients between 6 and 12 years old | All | 27 | 14 | 13 | - |
| Rem. | 19 (70.4%) | 9 (64.3%) | 10 (76.9%) | 0.302 | |
| Patients between 13 and 18 years old | All | 45 | 15 | 30 | - |
| Rem. | 30 (66.7%) | 9 (60.0%0 | 21 (70.0%) | 0.502 |
Rem—remission. Assessment after 12 weeks of treatment. Grey rows shows number of patients who achieved remission in every sub-group analyzed, shown as percentage in brackets.